If you liked this article you might like

New Setback for Sanofi's Lantus Increases Need for M&A
Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
Perceptive's Joe Edelman on Sarepta: I Always Believed Exondys Would Be Approved
Alexion Pharma (ALXN) Stock Gets 'Underperform' Rating at FBR Capital